Proton beam therapy for hepatocellular carcinoma with limited treatment options

Cancer

Volumn 107, Issue 3, 2006, Pages 591-598

  Hata, Masaharu ^a,b   Tokuuye, Koichi ^a,b   Sugahara, Shinji ^b   Fukumitsu, Nobuyoshi ^a,b   Hashimoto, Takayuki ^a,b   Ohnishi, Kayoko ^b   Nemoto, Keiko ^b   Ohara, Kiyoshi ^b   Matsuzaki, Yasushi ^b   Akine, Yasuyuki ^a,b  

^a UNIVERSITY OF TSUKUBA HOSPITAL   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Coexisting disease; Hepatocellular carcinoma; Proton beam therapy; Radiation therapy

Indexed keywords

ABDOMINAL DISCOMFORT; ACUTE TOXICITY; ADULT; AGED; ANOREXIA; BEAM THERAPY; BLEEDING TENDENCY; CANCER PATIENT; CANCER RADIOTHERAPY; CHEMOEMBOLIZATION; CLINICAL ARTICLE; ERYTHEMA; FEMALE; HUMAN; LIVER CARCINOMA; LIVER PARENCHYMA; LIVER TUMOR; LYMPH NODE METASTASIS; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROTON THERAPY; RADIATION INJURY; RETROSPECTIVE STUDY; REVIEW; TREATMENT FAILURE; TUMOR RECURRENCE;

AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROTONS; TREATMENT OUTCOME;

EID: 33746291275     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22039     Document Type: Review

References (38)

1. McGlynn KA, London WT. Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol. 2005;19:3-23.
2. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol. 2005;40:225-235.
3. Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinoma: a retrospective and nationwide survey in Japan. Hepatology. 2000;32:1224-1229.
4. Hsu C, Cheng JC, Cheng AL. Recent advances in non-surgical treatment for advanced hepatocellular carcinoma. J Formos Med Assoc. 2004;103:483-495.
5. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907-1917.
6. Huo T, Huang YH, Wu JC, et al. Comparison of transarterial chemoembolization and percutaneous acetic acid injection as the primary loco-regional therapy for unresectable hepatocellular carcinoma: a prospective survey. Aliment Pharmacol Ther. 2004;19:1301-1308.
7. Rai R, Manas D. Radiofrequency ablation of unresectable liver tumours. Hosp Med. 2003;64:737-739.
8. Matsuzaki Y, Osuga T, Saito Y, et al. A new, effective, and safe therapeutic option using proton irradiation for hepatocellular carcinoma. Gastroenterology. 1994;106:1032-1041.
9. Chiba T, Tokuuye K, Matsuzaki Y, et al. Proton beam therapy for hepatocellular carcinoma: a retrospective review of 162 patients. Clin Cancer Res. 2005;11:3799-3805.
10. Hata M, Tokuuye K, Sugahara S, et al. Proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombus. Cancer. 2005;104:794-801.
11. Suit H, Goldberg S, Niemierko A, et al. Proton beams to replace photon beams in radical dose treatments. Acta Oncol. 2003;42:800-808.
12. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655.
13. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646-649.
14. Sobin LH, Wittekind C, editors. TNM Classification of Malignant Tumors. 6th ed. New York: John Wiley & Sons; 2002.
15. Inada T, Hayakawa Y, Ohara K, et al. Treatment planning system for high energy proton beam. Nippon Acta Radiol. 1983;43:781-793.
16. Inada T, Tsuji H, Hayakawa Y, Maruhashi A, Tsujii H. Proton irradiation synchronized with respiratory cycle. Nippon Acta Radiol. 1992;52:1161-1167.
17. Ohara K, Okumura T, Akisada M, et al. Irradiation synchronized with respiration gate. Int J Radiat Oncol Biol Phys. 1989;17:853-857.
18. Ando K, Koike S, Kawachi K, et al. Relative biological effectiveness of the therapeutic proton beam at NIRS and Tsukuba University. Nippon Acta Radiol. 1985;45:531-535.
19. Withers HR, Thames HD Jr., Peters LJ. A new isoeffect curve for change in dose per fraction. Radiother Oncol. 1983; 1:187-191.
20. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207-214.
21. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341-1346.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
23. Altman DG. Practical Statistics for Medical Research. 2nd ed. London: Chapman and Hall; 2004.
24. Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1999;29:62-67.
25. Nagasue N, Yukaya H, Hamada T, Hirose S, Kanashima R, Inokuchi K. The natural history of hepatocellular carcinoma. A study of 100 untreated cases. Cancer. 1984;54:1461-1465.
26. Markovic S, Gadzijev E, Stabuc B, et al. Treatment options in Western hepatocellular carcinoma: a prospective study of 224 patients. J Hepatol. 1998;29:650-659.
27. Planas R, Balleste B, Alvarez MA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol. 2004;40:823-830.
28. Di Carlo V, Ferrari G, Castoldi R, et al. Surgical treatment and prognostic variables of hepatocellular carcinoma in 122 cirrhotics. Hepatogastroenterology. 1995;42:222-229.
29. Livraghi T. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. Hepatogastroenterology. 2001;48:20-24.
30. Tateishi R, Shiina S, Teratani T, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer. 2005;103:1201-1209.
31. Huo TI, Wu JC, Huang YH, et al. Acute renal failure after transarterial chemoembolization for hepatocellular carcinoma: a retrospective study of the incidence, risk factors, clinical course and long-term outcome. Aliment Pharmacol Ther. 2004;19:999-1007.
32. Huo TI, Wu JC, Lee PC, Chang FY, Lee SD. Incidence and risk factors for acute renal failure in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective study. Liver Int. 2004;24:210-215.
33. Park W, Lim do H, Paik SW, et al. Local radiotherapy for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2005;61:1143-1150.
34. Liu MT, Li SH, Chu TC, et al. Three-dimensional conformal radiation therapy for unresectable hepatocellular carcinoma patients who had failed with or were unsuited for transcatheter arterial chemoembolization. Jpn J Clin Oncol. 2004;34:532-539.
35. Seong J, Park HC, Han KH, Chon CY. Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular carcinoma: a retrospective study of 158 patients. Int J Radiat Oncol Biol Phys. 2003;55:329-336.
36. Cheng SH, Lin YM, Chuang VP, et al. A pilot study of three-dimensional conformal radiotherapy in unresectable hepatocellular carcinoma. J Gastroenterol Hepatol. 1999;14:1025-1033.
37. Park HC, Seong J, Han KH, Chon CY, Moon YM, Suh CO. Dose-response relationship in local radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2002;54: 150-155.
38. Uno T, Itami J, Shiina T, et al. Radiation therapy in patients with unresectable hepatocellular carcinoma. Cancer Chemother Pharmacol. 1992;31(Suppl):S106-S110.